SCHEMBL5544592

SCHEMBL5544592

CC(C)Oc1ccc(CN[CH]c2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.52
NPC1 O15118 1/20 0.52
MEN1 O00255 6/20 0.47
KMT2A Q03164 6/20 0.47
MITF O75030 1/20 0.47
LMNA P02545 2/20 0.46
ALDH1A1 P00352 1/20 0.46
ALPL P05186 1/20 0.43
ALPI P09923 1/20 0.43
ALPG P10696 1/20 0.43
PKM P14618 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
GAA P10253 1/20 0.43
CNR2 P34972 1/20 0.43
ALDH1A3 P47895 1/20 0.42
POLB P06746 1/20 0.41
NR1H4 Q96RI1 1/20 0.41
MAPT P10636 1/20 0.40
ALOX12 P18054 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544473 0.82 RAB9A (0.57) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL5537515 0.79 RAB9A (0.48) RAB9ANPC1MEN1KMT2ALMNA
SCHEMBL7385255 0.77 ADH1B (0.58) MEN1KMT2AALDH1A1TDP1GAA
SCHEMBL5544639 0.77 LTA4H (0.51) RAB9ANPC1MEN1KMT2ALMNA
SCHEMBL19223057 0.77 PPARG (0.60) RAB9ANPC1MEN1KMT2AMITF
SCHEMBL5547197 0.77 ALDH1A3 (0.52) RAB9ANPC1MEN1KMT2AMITF
SCHEMBL5542584 0.76 SMN1; SMN2 (0.49) RAB9ANPC1MEN1KMT2ALMNA
SCHEMBL5546612 0.75 TACR1 (0.43) MEN1KMT2ALMNAALDH1A1TDP1
SCHEMBL5544677 0.73 L3MBTL1 (0.45) LMNAALDH1A1TDP1
SCHEMBL5539505 0.73 LMNA (0.50) MEN1KMT2ALMNAALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 RAB9A 2824/4885NPC1 2404/4885MEN1 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.